Accueil・Liste d'Actions・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

218.9 -0.11

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

214.8

Max

222.13

Chiffres clés
By Trading Economics
Revenu	20M 206M
Ventes	70M 1.2B
P/E Moyenne du Secteur	68.571 64.641
BPA	1.99
Marge bénéficiaire	17.649
Employés	2,500
EBITDA	159M 304M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+71.22% upside

Dividendes
By Acuity
Prochains Résultats	29 oct. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-4B 37B
Ouverture précédente	219.01
Clôture précédente	218.9

Sentiment de l'Actualité

By Acuity

100%

320 / 340 Classement par Healthcare

Alnylam Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 août 2026, 20:02 UTC

News

Raymond James upgraded Alnylam Pharmaceuticals to Strong Buy with a $420 target, contributing to a notable increase in shares during Monday's session.

1 août 2026, 00:01 UTC

News

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

31 juil. 2026, 23:16 UTC

News

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

30 juil. 2026, 23:41 UTC

Alnylam Pharmaceuticals is rising in after-market hours, reflecting broader market gains. No specific news was identified to explain the price movement.

29 juil. 2026, 19:14 UTC

Macro Event

Correlated Moves

Alnylam Pharmaceuticals Inc shares are lower today, influenced by the Federal Reserve's decision to maintain interest rates amid economic uncertainties and sector declines.

28 juil. 2026, 20:02 UTC

News

Correlated Moves

Alnylam Pharmaceuticals is trading higher, benefiting from gains in the Biotechnology sector. Recent advancements in its Alzheimer's pipeline are attracting attention.

27 juil. 2026, 22:41 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, continuing a trend of gains over the last three sessions despite remaining below the 20-day moving average.

24 juil. 2026, 19:46 UTC

Correlated Moves

Alnylam Pharmaceuticals is trading higher, influenced by a rise in the Property & Casualty Insurance sector. Shares remain below their 20-day moving average.

23 juil. 2026, 09:51 UTC

Alnylam Pharmaceuticals shares are modestly higher in pre-market hours, trading within a narrow range since Wednesday's close. The stock remains below its 20-day moving average.

22 juil. 2026, 22:31 UTC

Alnylam Pharmaceuticals shares are higher in after-market trading, rebounding from earlier lows despite broader market volatility and geopolitical tensions.

21 juil. 2026, 23:56 UTC

No specific news was identified for Alnylam Pharmaceuticals during after-market hours. The stock remains near unchanged since Tuesday's close.

20 juil. 2026, 19:26 UTC

News

Alnylam Pharmaceuticals is trading higher as it initiates a Phase 2 trial of mivelsiran for Down syndrome-associated Alzheimer’s disease, signaling progress in research.

Comparaison

Variation de prix

Alnylam Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

71.22% hausse

Prévisions sur 12 Mois

Moyen 377.24 USD 71.22%

Haut 550 USD

Bas 230 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

18 ratings

Achat

Maintien

Vente

Basé sur 18 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

320 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.